Literature DB >> 11340500

[Hepatitis C].

E Strauss1.   

Abstract

It has been estimated that 3% of the world population is infected with the hepatitis C virus. Those who are blood product recipients or have been illicit drug users are at risk. Dental and medical procedures as well as tattooing and acupuncture are also risk factors. Chronic infection occurs in up to 85% of infected cases but they may remain without symptoms during years or even decades, and clinical presentation varies. Determination of anti-HCV in sera is a fairly sensitive tool for the diagnosis, and confirmation requires the identification of HCV-RNA. Staging of the liver disease as well as definition of its present activity can be graded by liver biopsy. The aim of treatment is to stop the progression of the hepatic disease by inhibiting viral replication. Due to the low therapeutic efficacy combined with important side-effects, the administration of interferon and ribavirin have specific indications and contraindications. Predictive factors of therapeutic response, particularly viral load and genotypes of HCV, are useful in the evaluation of patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11340500     DOI: 10.1590/s0037-86822001000100011

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  2 in total

1.  IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients.

Authors:  Bruna C Bertol; Simone Moreira; Raquel F L Garcia; Leslie E Ferreira; Guilherme Debortoli; Mauro de Souza Leite Pinho; Marcia Amendola-Pires; Alessandra M de Almeida Maciel; Carlos E Brandço-Mello; Paulo H C de França
Journal:  Front Microbiol       Date:  2015-03-04       Impact factor: 5.640

2.  Distribution of Hepatitis C virus (HCV) genotypes in seropositive patients in the state of Alagoas, Brazil.

Authors:  Rosa Maria S Gonzaga; Itatiana F Rodart; Mitermayer Galvão Reis; Cícero Eduardo Ramalho Neto; Denise Wanderlei Silva
Journal:  Braz J Microbiol       Date:  2008-12-01       Impact factor: 2.476

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.